Quoin Pharmaceuticals Ltd Stock Today

QNRX Stock  USD 0.60  0.01  1.64%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 53

 
High
 
Low
Average
Quoin Pharmaceuticals is trading at 0.6 as of the 24th of July 2024; that is 1.64 percent decrease since the beginning of the trading day. The stock's open price was 0.61. Quoin Pharmaceuticals has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Quoin Pharmaceuticals Ltd are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of June 2024 and ending today, the 24th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
29th of July 2016
Category
Healthcare
Classification
Health Care
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia. The company has 3.98 M outstanding shares of which 12.85 K shares are at this time shorted by private and institutional investors with about 0.27 trading days to cover. More on Quoin Pharmaceuticals Ltd

Moving against Quoin Stock

  0.62LLY Eli LillyPairCorr
  0.59KSPI Joint StockPairCorr
  0.56ABBV AbbVie IncPairCorr
  0.53GILD Gilead SciencesPairCorr

Quoin Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities5.5 M3.6 M
Way Up
Slightly volatile
Non Current Liabilities Total2.8 M2.9 M
Notably Down
Pretty Stable
Total Assets11.7 M12.2 M
Sufficiently Down
Pretty Stable
Total Current Assets8.3 M11.3 M
Way Down
Slightly volatile
Debt Levels
Quoin Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Quoin Pharmaceuticals' financial leverage. It provides some insight into what part of Quoin Pharmaceuticals' total assets is financed by creditors.
Liquidity
Quoin Pharmaceuticals Ltd currently holds 3.52 K in liabilities with Debt to Equity (D/E) ratio of 0.47, which is about average as compared to similar companies. Quoin Pharmaceuticals has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Quoin Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Net Borrowings

(779,477)
Quoin Pharmaceuticals Ltd (QNRX) is traded on NASDAQ Exchange in USA. It is located in 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349 and employs 4 people. Quoin Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.45 M. Quoin Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.98 M outstanding shares of which 12.85 K shares are at this time shorted by private and institutional investors with about 0.27 trading days to cover. Quoin Pharmaceuticals Ltd currently holds about 2.69 M in cash with (7.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56.
Check Quoin Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Roughly 93.0 pct. of Quoin Pharmaceuticals outstanding shares are held by general public with 0.487 % owned by insiders and only 6.45 (%) by third-party entities.
Check Quoin Ownership Details

Quoin Stock Institutional Holders

InstituionRecorded OnShares
Altium Capital Management, Lp2024-03-31
66.2 K
Renaissance Technologies Corp2024-03-31
46.5 K
Virtu Financial Llc2024-03-31
30.7 K
Hrt Financial Llc2024-03-31
30.3 K
Ubs Group Ag2024-03-31
5.1 K
Rhumbline Advisers2024-03-31
3.8 K
Jpmorgan Chase & Co2024-03-31
645
Susquehanna International Group, Llp2024-03-31
0.0
Wells Fargo & Co2023-12-31
0.0
View Quoin Pharmaceuticals Diagnostics

Quoin Pharmaceuticals Historical Income Statement

At this time, Quoin Pharmaceuticals' Net Interest Income is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 724.7 K in 2024, whereas Selling General Administrative is likely to drop slightly above 4 M in 2024. View More Fundamentals

Quoin Stock Against Markets

Additional Tools for Quoin Stock Analysis

When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.